Quantcast

Industry news that matters to you.  Learn more

Parsortix Research Partnership with the Paterson Institute for Cancer Research

ANGLE plc (AIM: AGL) is pleased to announce that Parsortix Inc (“Parsortix”), its 90% owned portfolio company which specialises in cancer diagnostics, has signed a two year research agreement with the Cancer Research UK-funded Paterson Institute for Cancer Research, The University of Manchester’s world-leading cancer research institute.

Biocept and Clarient Announce Collaboration on First Test for Circulating Tumor Cells and HER2 Status in Breast Cancer Patients

Biocept, Inc., a privately-held CLIA-certified laboratory testing company, focused on the detection and analysis of circulating tumor cells (CTCs) in cancer patients, and Clarient, Inc. (a GE Healthcare Company) today announced a collaboration on the commercialization of a proprietary blood test for CTCs in breast cancer patients, which includes the determination of HER2 status. Clarient and Biocept will market and sell Biocept’s new OncoCEE-BR CTC test to community hospitals, pathologists and medical oncologists. Biocept will perform the test in its laboratories, and results will be interpreted by Clarient’s highly respected pathology group (Clarient Pathology Services, Inc.). The test includes CTC enumeration and HER2 status of the detected CTCs by fluorescence in situ hybridization (FISH); it is the first commercially available CTC test to include analysis of a specific treatment-associated biomarker.

ApoCell Launches Revolutionary Circulating Cancer Cell Detection System

ApoCell, Inc. announced earlier this week that it has completed the first prototype to commercialize a revolutionary technology that improves the detection of more types of cancer cells circulating in the blood, including rare cell types that have previously gone undetected. Invented by scientists at The University of Texas MD Anderson Cancer Center’s Laboratory of Diagnostic Microsystems and exclusively licensed to ApoCell, a leader in biomarker analysis, the technology also enables the capture of circulating tumor cells (CTCs) in a live and viable state, enabling post-detection testing and culturing.

Veridex to Develop Next-Generation Circulating Tumor Cell Technology with MGH

Earlier this month, Veridex announced a collaboration with Massachusetts General Hospital (MGH) to develop and commercialize a next-generation circulating tumor cell (CTC) technology for capturing, counting and characterizing tumor cells found in patients’ blood. The platform to be developed will be a bench-top system to specifically isolate and explore the biology of rare cells at the protein, RNA and DNA levels.

Circulating Tumor Cells Can Provide ‘Real-time’ Information on Patient’s Current Disease State

Circulating tumor cells (CTCs) may be a promising alternative, noninvasive source of tumor materials for biomarker assessment, according to data presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development.